Maintenance Dovitinib for Colorectal and Pancreas Cancer

Inclusion Criteria:

* Patients with a confirmed diagnosis of:

  1. Stage 4 colon cancer either s/p metastasectomy or post-initial chemotherapy or maintenance "standard of care", either involving 5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab alone. Patients in maintenance cohort must have had 2 consecutive CT scans showing stable disease and not be experiencing significant prior treatment-related toxicity above Grade 1.
  2. Pancreas cancer, either s/p resection and adjuvant chemotherapy or locally advanced pancreas cancer s/p chemotherapy and radiation. Initial chemotherapy or radiation therapy may have been stopped between 2 weeks and 2 months prior to study start, and patients must have recovered from prior treatment related toxicity to grade 1 or less.
* Prior surgery, including tumor resection or metastasectomy must have been performed at least 4 weeks prior to study enrollment.
* No concomitant anti-cancer treatment is allowed
* Age \>/= 18 years
* Performance status of 0-1
* Adequate hepatic, bone marrow, and renal function
* Partial thromboplastin time (PTT) must be \</= 1.5 x upper normal limit of institution's normal range and INR (International Normalized Ratio) \< 1.5.
* Life expectancy \>/= 4 months for maintenance cohorts and \>/= 6 months for adjuvant cohorts
* Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and must not be lactating.
* Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent

Exclusion Criteria:

* Women of child-bearing potential, who are biologically able to conceive, not employing two forms of highly effective contraception or who are pregnant.
* Women who are breast-feeding
* Fertile males unwilling to use contraception
* Patients with brain metastases or any history of brain metastases
* Patients who have undergone major surgery (e.g., intra-thoracic, -abdominal, or -pelvic) \</= 4 weeks prior to starting study treatment or who have not recovered from such therapy
* Patients with a history of pulmonary embolism, or untreated deep vein thrombosis within the past 6 months
* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of dovitinib
* The subject has had another active malignancy within the past 5 years except for cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.
* Patients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies \</= 2 weeks prior to starting the study drug, or who have not recovered from the side effects of such therapy
* Cirrhosis, chronic active hepatitis or chronic persistent hepatitis
* Patients who are currently receiving prasugrel
* No concurrent use of isoniazid, labetolol, trovafloxacin, tolcapone, and felbamate
* No concurrent use of other investigational drugs or antineoplastic therapies.
* Patients with impaired cardiac function or clinically significant cardiac diseases.